Groton, CT, September 16, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries,...
Groton, CT, September 8, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of brain injuries, announced...
Lisa Manna, RN, MBA Groton, CT, July 1, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative...
Groton, CT, May 3, 2021 – Astrocyte Pharmaceuticals Inc., a drug discovery and development company advancing novel neuroprotective therapeutics for the treatment of neurodegenerative brain injuries,...
Groton, CT, December 1, 2020 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company advancing neuroprotective treatments, announced the establishment of its Clinical Advisory Board...
Cambridge, MA, February 21, 2020 – Astrocyte Pharmaceuticals Inc. presented the results of a key preclinical efficacy study today at the International Stroke Conference in Los Angeles demonstrating...
Cambridge, MA, December 11, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, today announced that Jeffrey L. Saver, M.D., has joined the company’s Scientific Advisory...
Cambridge, MA, June 6, 2018 – Astrocyte Pharmaceuticals Inc. announced today that it has completed a Pre-A financing round that raised over $2.3M. The company is advancing several small molecule neuroprotective...
Cambridge, MA, September 19, 2018 – Astrocyte Pharmaceuticals Inc., a privately held pharmaceutical company, announced today that it has been awarded a $3 million Phase 2 Small Business Innovation Research...
Cambridge, MA, September 18, 2018 – Astrocyte Pharmaceuticals, Inc., a privately held pharmaceutical company, announced today that it has been awarded $287k Phase 1 Small Business Technology Transfer...
Developing innovative neuroprotection therapies for Traumatic Brain Injuries (TBI), concussions, stroke, and neurodegenerative disorders